A Phase 1, Open-Label, Multi-Center, Multi-Dose Study of Intradermal GRN-1201 in HLA-A*02 Subjects With Resected Stage IIb, IIc or III Melanoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 21 Nov 2017
At a glance
- Drugs GRN 1201
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors BrightPath Biotherapeutics
- 13 Nov 2017 Planned End Date changed from 1 Jun 2017 to 1 Mar 2018.
- 13 Nov 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Mar 2018.
- 13 Nov 2017 Status changed from recruiting to active, no longer recruiting.